Adam 55 mg

Adam 5 5 mg is a synthetic corticosteroid (glucocorticoid) used to treat a wide range of inflammatory, allergic, and autoimmune conditions. Its uses can be classified by strength of evidence as follows:

Established / Guideline-Supported Uses

• Respiratory conditions: acute exacerbations of bronchial asthma, chronic obstructive pulmonary disease (COPD) exacerbations
• Allergic states: severe allergic reactions, seasonal or perennial allergic rhinitis (severe), drug hypersensitivity reactions, angioedema
• Rheumatic disorders: rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, polymyalgia rheumatica, acute gouty arthritis (as adjunct)
• Dermatologic diseases: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis, severe seborrheic dermatitis
• Endocrine disorders: primary or secondary adrenocortical insufficiency (used with a mineralocorticoid where applicable), congenital adrenal hyperplasia, non-suppurative thyroiditis
• Gastrointestinal disease: to help patients through a critical period of ulcerative colitis and Crohn's disease
• Hematologic disorders: acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura in adults
• Renal disease: to induce diuresis or remission of proteinuria in nephrotic syndrome (idiopathic type or due to lupus erythematosus)
• Ophthalmic disease: severe acute and chronic allergic and inflammatory processes involving the eye
• Neurologic conditions: acute exacerbations of multiple sclerosis
• Organ transplantation: as part of immunosuppressive regimens to prevent/treat graft rejection

Adjunct Therapy

Used as adjunct/palliative therapy in certain leukemias and lymphomas, and in combination with other disease-modifying or chemotherapeutic agents in autoimmune and malignant conditions.

Off-Label Use

Adam 5 5 mg is also commonly used off-label for conditions such as sarcoidosis-related organ involvement, autoimmune hepatitis, and short-course management of severe croup or acute gout flares, based on clinical judgment and specialist guidance.

Adam 5 5 mg is not an antibiotic and has no role in treating infections themselves.

Each tablet of Adam 5 5 mg commonly contains Adam 5 5 mg 5 mg, 10 mg, or 20 mg. Adam 5 5 mg is also available as an oral solution/syrup (approximately 5 mg/5 mL) for pediatric or patients who cannot swallow tablets. Strength and dosage form availability may vary by manufacturer and market.

Adam 5 5 mg is a synthetic glucocorticoid corticosteroid, the active metabolite of prednisone, used for its potent anti-inflammatory and immunosuppressive effects. It is used across many specialties to control inflammation and abnormal immune activity in a wide range of allergic, rheumatologic, dermatologic, respiratory, hematologic, and endocrine conditions.

Adam 5 5 mg works by suppressing the migration of inflammatory cells and reversing increased capillary permeability, and by modifying the body's immune response to various stimuli. It has minimal mineralocorticoid activity compared to hydrocortisone, making it useful for conditions requiring anti-inflammatory effect without significant salt/water retention (though this can still occur at higher doses).

Corticosteroid (Glucocorticoid) — Systemic. Adam 5 5 mg belongs to this therapeutic class.

Mechanism

Adam 5 5 mg diffuses across cell membranes and binds to cytoplasmic glucocorticoid receptors. The activated receptor-steroid complex translocates into the cell nucleus, binds to DNA (glucocorticoid response elements), and modulates gene transcription — inducing synthesis of anti-inflammatory proteins (e.g. lipocortin-1, which inhibits phospholipase A2) and suppressing pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines). This produces potent anti-inflammatory, immunosuppressive, anti-allergic, and antipruritic effects.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed after oral administration; peak plasma concentration in 1-2 hours.
• Protein binding: Approximately 70-90%, mainly to transcortin (corticosteroid-binding globulin) and albumin.
• Metabolism: Primarily hepatic, via reversible interconversion with prednisone and further oxidative metabolism.
• Half-life: Plasma half-life is approximately 2-4 hours, but biologic (anti-inflammatory) half-life is much longer (18-36 hours), allowing once-daily or alternate-day dosing.
• Excretion: Mainly renal, as metabolites.

• Take Adam 5 5 mg tablets by mouth, preferably with or after food/milk to reduce stomach upset.
• Once-daily doses are best taken in the morning, mimicking the body's natural cortisol rhythm and reducing insomnia and adrenal suppression risk.
• The oral solution should be measured using an accurate measuring device, not a household spoon.
• Do not stop Adam 5 5 mg suddenly after prolonged use — follow the physician's tapering schedule exactly.
• Swallow tablets whole or as directed; do not adjust the dose without consulting a physician.

Side effects of Adam 5 5 mg are generally dose- and duration-dependent.

Common

• Increased appetite, weight gain
• Insomnia, mood changes, nervousness
• Indigestion, nausea
• Fluid retention, facial puffiness ("moon face")
• Acne, increased sweating

Less Common but Serious (usually with prolonged/high-dose use)

• Adrenal suppression, Cushingoid features
• Hyperglycemia / worsening of diabetes
• Osteoporosis, increased fracture risk, avascular necrosis of bone
• Peptic ulceration, GI bleeding (especially with NSAIDs)
• Increased susceptibility to infections; masking of infection signs
• Cataracts, glaucoma, increased intraocular pressure
• Muscle weakness/myopathy
• Psychiatric effects (mood swings, psychosis, severe depression) — rare but reported
• Growth suppression in children with prolonged use

Pregnancy: Adam 5 5 mg should be used during pregnancy only if clearly needed and the potential benefit to the mother justifies the potential risk to the fetus. Corticosteroids readily cross the placenta; animal studies have shown reproductive risks (e.g. cleft palate) with corticosteroids, though controlled human data are limited. Infants born to mothers who received substantial doses of Adam 5 5 mg during pregnancy should be monitored for signs of hypoadrenalism. Use only under specialist guidance for serious maternal conditions where benefit outweighs risk.

Lactation: Adam 5 5 mg is excreted in small amounts in breast milk. Low to moderate doses are generally considered compatible with breastfeeding by many specialists, but a physician should be consulted, especially for higher or prolonged doses, and the infant should be monitored for growth and adrenal function if maternal dose is high or prolonged.

• Adrenal suppression: Prolonged use of Adam 5 5 mg can suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not stop abruptly after extended courses — taper the dose gradually under medical supervision.
• Infection risk: Adam 5 5 mg can increase susceptibility to infections and mask their signs and symptoms (including fever); new infections may appear during use. Avoid exposure to chickenpox or measles if non-immune.
• Hyperglycemia: May unmask latent diabetes or worsen existing diabetes control; monitor blood glucose.
• Bone health: Long-term use increases risk of osteoporosis and fractures; calcium/vitamin D supplementation and bone density monitoring may be advised for prolonged therapy.
• Psychiatric effects: May cause mood disturbances, euphoria, insomnia, irritability, or, rarely, severe depression or psychotic manifestations, particularly at higher doses.
• Fluid retention/hypertension: Can cause sodium and fluid retention; use cautiously in hypertension, heart failure, or renal impairment.
• GI ulceration: Increased risk of peptic ulcer and GI bleeding, particularly when combined with NSAIDs.
• Growth suppression: Long-term use in children may suppress growth; growth should be monitored periodically.
• Ocular effects: Prolonged use may cause cataracts, glaucoma, and increased intraocular pressure; may worsen ocular viral/fungal infections.
• Vaccination: Avoid live vaccines during immunosuppressive-dose therapy (see Contraindications and Interactions).

Acute overdose of Adam 5 5 mg is unlikely to be immediately life-threatening, but chronic overdosage or very high single doses can worsen known corticosteroid adverse effects (e.g. marked fluid retention, hypertension, hyperglycemia, mood changes, GI bleeding). There is no specific antidote.

If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services. Treatment is supportive and symptomatic; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: May be more susceptible to osteoporosis, hypertension, hypokalemia, diabetes, and skin fragility; use the lowest effective dose with close monitoring.
• Renal impairment: No formal dose adjustment established, but use cautiously with monitoring for fluid retention and electrolyte disturbance.
• Hepatic impairment: Adam 5 5 mg (the active form) does not require hepatic activation like prednisone, but should still be used cautiously with monitoring in significant liver disease.
• Diabetics: Requires closer blood glucose monitoring; antidiabetic therapy may need adjustment (see Interactions).
• Immunocompromised patients: Increased infection risk; live vaccines should be avoided during immunosuppressive dosing (see Contraindications).

Duration of Adam 5 5 mg therapy depends entirely on the condition being treated. Short courses (a few days to 1-2 weeks, e.g. for asthma exacerbations or acute allergic reactions) generally do not require tapering. Longer courses (several weeks to months or longer, e.g. for autoimmune or rheumatologic disease) require gradual dose tapering under medical supervision to avoid adrenal insufficiency and disease flare. The lowest effective dose for the shortest duration necessary should always be the goal.

Corticosteroids (Glucocorticoids); Systemic anti-inflammatory/immunosuppressive agents

Adam 5 5 mg binds to intracellular glucocorticoid receptors, and the resulting complex regulates gene transcription in target cells. This leads to increased synthesis of anti-inflammatory mediators (such as lipocortin-1, which inhibits phospholipase A2 and thereby reduces arachidonic acid-derived inflammatory mediators like prostaglandins and leukotrienes) and decreased synthesis of pro-inflammatory cytokines (IL-1, IL-2, IL-6, TNF-alpha). It also reduces the number and activity of circulating lymphocytes, monocytes, and eosinophils, and stabilizes lysosomal and capillary membranes, together producing potent anti-inflammatory and immunosuppressive effects.

C

Adam 5 5 mg is used in children for indications such as nephrotic syndrome, acute asthma exacerbations, croup, certain autoimmune and rheumatologic conditions, and as part of chemotherapy regimens for certain childhood leukemias/lymphomas, always under pediatric specialist guidance.

• Dosing is generally weight-based (commonly 0.1-2 mg/kg/day depending on indication) rather than fixed adult dosing.
• Growth and development should be monitored closely during prolonged therapy, as Adam 5 5 mg can cause growth suppression; the smallest effective dose for the shortest duration should be used.
• Live vaccines should be deferred during immunosuppressive-dose therapy (see Contraindications).
• Safety and efficacy of Adam 5 5 mg for indications outside established pediatric uses have not been established, and use in very young infants requires specialist judgment.